Difference between revisions of "Polycythemia vera risk factors"

Jump to: navigation, search
(Risk Factors)
 
Line 1: Line 1:
 
__NOTOC__
 
__NOTOC__
 
{{Polycythemia vera}}
 
{{Polycythemia vera}}
{{CMG}} {{AE}}{{MJK}}; {{shyam}}
+
{{CMG}} {{AE}} {{IO}} {{MJK}} {{shyam}}
 
==Overview==
 
==Overview==
 
Common risk factors in the development of polycythemia vera are old age (65 year old and older), family history, and Ashkenazi Jewish descent. After a patient is diagnosed with polycythemia vera, risk stratification involves assessment of age and thrombotic history. The risk assessment for development of post-PV [[myelofibrosis]] or post-PV [[acute myeloid leukemia]] include a variety of factors.
 
Common risk factors in the development of polycythemia vera are old age (65 year old and older), family history, and Ashkenazi Jewish descent. After a patient is diagnosed with polycythemia vera, risk stratification involves assessment of age and thrombotic history. The risk assessment for development of post-PV [[myelofibrosis]] or post-PV [[acute myeloid leukemia]] include a variety of factors.

Latest revision as of 03:03, 14 September 2019

Polycythemia vera Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Polycythemia vera from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polycythemia vera risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycythemia vera risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycythemia vera risk factors

CDC on Polycythemia vera risk factors

Polycythemia vera risk factors in the news

Blogs on Polycythemia vera risk factors

Directions to Hospitals Treating Polycythemia vera

Risk calculators and risk factors for Polycythemia vera risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ifeoma Odukwe M.D. [2] Mohamad Alkateb, MBBCh [3] Shyam Patel [4]

Overview

Common risk factors in the development of polycythemia vera are old age (65 year old and older), family history, and Ashkenazi Jewish descent. After a patient is diagnosed with polycythemia vera, risk stratification involves assessment of age and thrombotic history. The risk assessment for development of post-PV myelofibrosis or post-PV acute myeloid leukemia include a variety of factors.

Risk Factors

Risk factors in the development of polycythemia vera are:[1]

  • Old age (65 years older)
  • Family history of polycythemia vera
    • First-degree relatives of patients with polycythemia vera have a 5 to 7-fold higher risk for development of a myeloproliferative neoplasm.
    • The cumulative risk of developing myelofibrosis is 6% at 10 years, 14% at 15 years, and 26% at 20 years from the initial diagnosis of polycythemia vera.[2]
  • Ashkenazi Jewish descent

Risk Stratification

High risk features of polycythemia vera include:

The risk factors for the development of thrombosis include:[3]

The risk factors for the transformation to myelofibrosis or secondary acute myeloid leukemia include:[3]

The risk factors associated with decreased survival include:[3]

References

  1. Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F; et al. (2014). "In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology". Blood. 124 (19): 3021–3. doi:10.1182/blood-2014-07-591610. PMID 25377561.
  2. Vannucchi AM (2017). "From leeches to personalized medicine: evolving concepts in the management of polycythemia vera". Haematologica. 102 (1): 18–29. doi:10.3324/haematol.2015.129155. PMC 5210229. PMID 27884974.
  3. 3.0 3.1 3.2 Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R (November 2015). "Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F". J. Clin. Oncol. 33 (33): 3953–60. doi:10.1200/JCO.2015.61.6474. PMC 4979103. PMID 26324368.

Linked-in.jpg